ReviewClinical Medicine Insights. Oncology2016
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?
Review in Clinical Medicine Insights. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.International journal of molecular sciences · 2023Trial
- Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients.International journal of molecular sciences · 2020Trial
- Prediction of the response to antiangiogenic sunitinib therapy by non-invasive hybrid diffuse optics in renal cell carcinoma.Biomedical optics express · 2024Article
- Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.Frontiers in oncology · 2022Review
- Article
- Expressing of Recombinant VEGFR2-specific Nanobody in Baculovirus Expression System.Iranian journal of biotechnology · 2021Article
- Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer.Journal of cancer research and clinical oncology · 2020Article
- Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer.Journal of experimental pharmacology · 2020Review
- Pretreatment risk management of a novel nomogram model for prediction of thoracoabdominal extrahepatic metastasis in primary hepatic carcinoma.Journal of translational medicine · 2019Article
- Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).Pediatric blood & cancer · 2018Article
- The role of tumor angiogenesis as a therapeutic target in colorectal cancer.Expert review of anticancer therapy · 2018Review
- Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.International journal of molecular sciences · 2018Article
- Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives.Journal of cancer metastasis and treatment · 2018Article
- Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review.Current pharmacogenomics and personalized medicine · 2017Review
- KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.Scientific reports · 2017Article
- The role of microvessel density, lymph node metastasis, and tumor size as prognostic factors of distant metastasis in colorectal cancer.Oncology letters · 2017Article
- Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.Scientific reports · 2017Article
- Targeting angiogenesis in gastrointestinal tumors: current challenges.Translational gastroenterology and hepatology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in the treatment of colorectal cancer (CRC), it remains the second most common cause of cancer-related death in the Western world. Angiogenesis is a complex process that involves the formation of new blood vessels from preexisting vessels. It is essential for promoting cancer survival, growth, and dissemination. The inhibition of angiogenesis has been shown to prevent tumor progression experimentally, and several chemotherapeutic targets of tumor angiogenesis have been identified. These include anti-vascular endothelial growth factor (VEGF) treatments, such as bevacizumab (a VEGF-specific binding antibody) and anti-VEGF receptor tyrosine kinase inhibitors, although antiangiogenic therapy has been shown to be effective in the treatment of several cancers, including CRC. However, it is also associated with its own side effects and financial costs. Therefore, the identification of biomarkers that are able to identify patients who are more likely to benefit from antiangiogenic treatment is very important. This article intends to be a concise summary of the potential biomarkers that can predict or prognosticate the benefit of antiangiogenic treatments in CRC, and also what we can expect in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.